Clinical Trial Update: A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, efficacy, and immune response of sequential treatment with an anti-sense oligonucleotide against CHB followed by CHB-TI in CHB …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Anti-sense oligonucleotide against chronic hepatitis B
• CHB-targeted immunotherapy (CHB-TI)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED